Nobody in biotech wakes up and decides to hire a CRO. Something happens first. A Series B closes. A Phase 2 reads out. A pharma acquires a company and inherits a manufacturing problem. A new CMO starts and begins rebuilding a team.
Every deal you have ever won was preceded by an event like that. The question that separates BD teams that hit their number from the ones that grind is simple: did you know about the event in time to be the first call, or did you find out when the RFP hit your inbox alongside nine competitors?
Why “just checking in” gets deleted
Cold outreach fails in life sciences for a specific, fixable reason. It arrives without a trigger.
A biotech VP gets dozens of vendor emails a month. The ones that get deleted unread all say variations of the same thing: we do great work, we would love to connect, just checking in. There is no reason for that email to exist today rather than any other day, and the recipient knows it.
Now compare an email that opens with: congratulations on the Series B, you are probably scoping trial partners for the lead program. That is not a cold email. That is a relevant, timely observation from someone who is paying attention, and it gets a reply, because it is about the buyer rather than the seller.
Same vendor. Same service. Same pitch. Radically different outcome. The only difference is the trigger.
The trigger events that actually predict biotech buying
Most buying in this industry is downstream of a handful of event types. Learn to watch these and you can predict demand instead of chasing it.
- Funding rounds. A biotech that just raised has money and a mandate to spend it moving programs forward. The CRO that calls the week after a Series B closes gets the meeting. The one that calls three months later gets voicemail, because the decision was made in month two.
- M&A. An acquisition creates an integration problem: manufacturing transfers, redundant vendors, new commercial teams, a pile of legal work. Every acquisition is a bundle of service needs with a date attached.
- Clinical milestones. A program advancing into a new phase means new supply requirements, new trial infrastructure, and new regulatory work. Phase 2 to Phase 3 is one of the loudest buying signals in the industry, and it is public.
- Regulatory events. An approval, a breakthrough designation, an upcoming PDUFA date. Approval means commercial launch, which means hiring, agencies, market access, and manufacturing scale-up.
- Leadership changes. A new CMO, CBO, or Head of Regulatory almost always rebuilds. They bring new vendors, revisit incumbent relationships, and are unusually open to conversation in their first ninety days. This is the single most underexploited signal in life sciences BD.
The window is short, and it closes quietly
Here is the part that costs vendors real money. These windows are measured in weeks, not quarters.
When a company raises a large round, they are not idly considering vendors for the next year. They are moving. Within roughly a quarter, the CRO is chosen, the manufacturing conversation is underway, and the recruiter has been briefed. If your outreach arrives after that, you are not competing, you are documenting a loss.
The brutal thing is that the loss is invisible. You never get an email telling you a shortlist was built without you. You simply never hear anything, and you conclude the market is slow.
What this looks like in practice
Take a real one. In April 2026, Teva agreed to acquire Emalex Biosciences for roughly $900 million, $700 million upfront plus milestones, for a first-in-class D1 receptor antagonist in pediatric Tourette syndrome, with an NDA filing expected in the second half of the year.
Read that as news and it is interesting. Read it as a signal and it is four separate sales opportunities with deadlines:
- A CRO should be talking to Teva now about post-marketing and Phase 4 support, with pediatric neuroscience as the entry point. The window is open through the integration.
- A CDMO should note this is an oral small molecule with a manufacturing transfer likely during integration and commercial scale-up needed for launch.
- A recruiter should know Teva will build a neuroscience commercial team: medical affairs, regulatory, market access, commercial.
- An agency should see greenfield disease awareness work, because no approved D1-selective treatment exists and both HCP education and patient identification are wide open.
One headline. Four vendors who should be calling this week. Most of them will read it, think “interesting,” and do nothing, because the translation from news to action never happens.
Why BD teams miss this, even when they are trying
It is not laziness. It is arithmetic.
Tracking this properly means monitoring FDA filings, SEC disclosures, trial registries, earnings calls, press releases, and funding announcements, then working out which events matter for your specific service line, then figuring out who to contact and what to say. BD reps who attempt it burn ten or more hours a week on research and are still behind, because by the time the prospect list is built, half the week is gone and the window has narrowed.
Most teams quietly give up and default to generic outreach, which is why “just checking in” exists.
The fix: stop reading news, start reading signals
The difference between news and a signal is the translation. News tells you what happened. A signal tells you who to call because of what happened, and what to say when they pick up.
That is exactly why we built BioMed Nexus Signals. Every Friday morning, BD teams get 15 to 20 tagged signals from the week’s biopharma activity, each one carrying the trigger event, the companies involved, the relevant data, and specific action items for your category, whether you are a CRO, CDMO, recruiter, law firm, agency, or clinical tech vendor. Every brief ends with a “Who To Call This Week” list: ten prioritized companies, the person to contact, the trigger, and a suggested opening line.
It is built on the same editorial engine behind the daily brief that 65,000+ biotech professionals already read, restructured into something your team can act on rather than merely be informed by. Ten minutes on Friday, a week of outreach.
The math
A BD rep costs well north of $150,000 fully loaded. If they are spending ten hours a week on research, you are paying a meaningful fraction of that salary for someone to read the news slowly. Signals cuts that to fifteen minutes on a Friday.
And that is the boring justification. The real one is that a single client engagement won from a well-timed, trigger-based call is worth hundreds of thousands of dollars in this industry. One closed deal pays for the subscription for the next decade. The math is not close, and it is not subtle.
Start calling the right people
Your competitors are reading the same headlines you are. The difference is whether anyone on your team turns them into calls before the window shuts.
Get Signals for your BD team, $8,000/year for up to 5 seats
Or start with a single seat, $2,500/year
There is a two-week free trial: two full briefs, no commitment. If your team does not find it actionable, you pay nothing. For related reading, see how biotech buyers actually choose vendors and lead generation for biotech service providers.
Frequently asked questions
What are buying signals in biotech?
Buying signals are trigger events that predict when a biotech or pharma company is about to purchase services: funding rounds, mergers and acquisitions, clinical milestones such as a Phase 2 to Phase 3 advance, regulatory events like approvals and PDUFA dates, and leadership changes. Each one creates predictable service needs with a short window.
Why does cold outreach fail in life sciences?
Because it arrives without a trigger. A generic ‘just checking in’ email gives the recipient no reason it was sent today rather than any other day, so it gets deleted. An email referencing a real event, such as a Series B that just closed or a new CMO appointment, is timely and relevant to the buyer, and gets replies.
What is the best sales trigger for a CRO or CDMO?
Funding rounds and clinical milestones are the strongest. A biotech that just raised has money and a mandate to advance programs, and typically selects a CRO within a quarter. For CDMOs, a program advancing into a new phase or an acquisition creating a manufacturing transfer are the clearest signals. Leadership changes are the most underexploited signal in the industry.
What is BioMed Nexus Signals?
Signals is weekly sales intelligence for life sciences BD teams. Every Friday morning subscribers receive 15 to 20 tagged signals from the week’s biopharma activity, each with the trigger event, the companies involved, and specific action items for their service category, plus a ‘Who To Call This Week’ list of ten prioritized targets with suggested opening lines.
How much does BioMed Nexus Signals cost?
Signals is $2,500 a year for an individual seat, $8,000 a year for a team of up to five seats (adding a quarterly market intelligence report, a warm account tracker and a co-branded lead magnet), and $20,000 a year for enterprise with unlimited seats, custom signal filters and a monthly priority targets report. A two-week free trial is available.
How is Signals different from a newsletter?
A newsletter tells you what happened. Signals tells you who to call because of what happened, and what to say when they pick up. The daily brief is editorial analysis for biotech professionals staying informed; Signals is a sales tool that restructures the same intelligence into trigger events, target lists and outreach actions for BD teams.
